Abstract 766P
Background
Prolongation of overall treatment time (OTT) in carcinoma cervix is well known to adversely affect local control and survival. The OTT would be unduly prolonged if brachytherapy (BT) was started only after completion of external beam radiation (EBRT) as multiple insertions are required for high-dose-rate BT. This study was carried out to compare treatment outcomes of shortening the OTT by interdigitated BT as opposed to conventional sequential BT in terms of late toxicities, disease free survival (DFS) and overall survival (OS).
Methods
The study included 70 patients of cancer cervix who met the inclusion criteria. Patients were randomized into study and control arms. All the patients received EBRT (45Gy/20 fractions over 4 weeks) with concurrent Cisplatin and 3 fractions of BT (7 Gy/fraction). Patients in the control arm received weekly BT after one week following EBRT to complete the entire treatment in 7 weeks. In the study arm, BT was interdigitated with EBRT after 15 fractions. Subsequent BT fractions were given on days 27 and 34 to complete the treatment in 5 weeks. The two groups were compared in terms of late toxicities, DFS and OS at a follow up of two years.
Results
A total of 63 patients completed the planned treatment. The OTT and mean biologically equivalent dose (BED10Gy) after reduction for accelerated repopulation was significantly better in the study arm (p=0.001). At two years of follow up, 80% of patients in the study arm and 72.72% in the control arm had no local or distant failure. Also, death occurred in 13.33% patients and 18.18% patients in the study and control arm, respectively. No statistically significant difference was reached in terms of OS and DFS despite a trend towards better DFS in the interdigitated BT arm. The incidence of late lower gastro-intestinal toxicities was found to be higher in the study arm but this difference was not significant.
Conclusions
Interdigitated BT with chemoradiation appears to be an acceptable option for shortening OTT with similar survival outcomes and acceptable toxicities in comparison to sequential brachytherapy. Owing to a shorter OTT, this approach is radiobiologically superior with a more efficient utilization of machines at centers with heavy patient load.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
758P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Mathilde Saint-Ghislain
Session: Poster session 11
759P - Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
Presenter: Junjie Wang
Session: Poster session 11
760P - Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
Presenter: Ang Qu
Session: Poster session 11
761P - A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification
Presenter: Josep M. Piulats
Session: Poster session 11
764P - Tislelizumab (Anti-PD-1) combined with definitive chemoradiotherapy in recurrent and/or metastatic cervical cancer (PILOT-2020-511): A single-arm, phase II trial
Presenter: JUN ZHU
Session: Poster session 11
765P - SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Presenter: Xiaohua Wu
Session: Poster session 11
767P - Phase I/II study of toripalimab with cisplatin-based concurrent IMRT for local advanced cervical cancer
Presenter: Ping Jiang
Session: Poster session 11
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11